US4382083A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic method for treating blood-clotting defects with factor VIIa
Assignee: Baxter International Inc
•
Filing: 1981-06-25
•
Granted: 1983-05-03
•
Expires: 2001-06-25
Abstract
Abstract Patients having a clotting factor defect can be successfully treated by the administration of a composition containing effective hemostatic amounts of factor VIIa. Preferably, the factor VIIa is substantially free of factors IXa and Xa. Procedures for preparing the above therapeutic compositions are also described.
Inventors
- 👤 William R. Thomas
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 09:36
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61K38/482; A61K38/4846
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
43 words
A method for treating a patient having a clotting factor defect, comprising administering to the patient an effective hemostatic amount of factor VIIa, which factor VIIa is uncontaminated by other activated blood clotting factors having sufficient activity alone to produce a hemostatic effect.
Claim 2
Independent Claim
43 words
A method for treating a patient having a clotting factor defect, comprising administering to the patient an effective hemostatic amount of factor VIIa, which factor VIIa is uncontaminated by other activated blood clotting factors having sufficient activity alone to produce a hemostatic effect.
Claim 3
Dependent Claim
15 words
The method of claim 1 wherein the composition consists essentially of factors VII and VIIa.
Claim 4
Dependent Claim
22 words
The method of claim 1 wherein the hemostatic amount comprises about from 0.1 to 2.5 μg of factor VIIa/kg of body weight.
Claim 5
Dependent Claim
12 words
The method of claim 1 wherein the composition is administered by infusion.
Claim 6
Dependent Claim
12 words
The method of claim 1 wherein the composition is an aqueous solution.
Claim 7
Dependent Claim
24 words
The method of claim 5 wherein the factor VIIa is present in said solution at a concentration of about from 0.1 to 10.0 μg/ml.
Claim 8
Dependent Claim
11 words
The method of claim 1 wherein the composition comprises factor X.
Claim 9
Dependent Claim
15 words
The method of claim 1 wherein the composition is free of factors IXa and Xa.
Claim 10
Dependent Claim
14 words
The method of claim 1 wherein the patient is deficient in factor VIII activity.
Claim 11
Dependent Claim
13 words
The method of claim 1 wherein the patient's factor VIII activity is inhibited.
Claim 12
Dependent Claim
14 words
The method of claim 1 wherein the defect is manifest following chronic liver disease.
Claim 13
Dependent Claim
11 words
The method of claim 1 wherein the composition contains a stabilizer.
Claim 14
Dependent Claim
20 words
The method of claim 13 wherein the stabilizer is a protein at a concentration of greater than about 1 mg/ml.
Claim 15
Dependent Claim
10 words
The method of claim 14 wherein the protein is albumin.
Claim 16
Dependent Claim
19 words
The method of claim 1 wherein the amount of factor Xa in the composition is less than 1 unit/ml.
Claim 17
Dependent Claim
29 words
The method of claim 1 wherein the amount of factor IXa as measured by total factor IX activity minus factor IX precursor activity is less than about 15 units/ml.
Claim 18
Dependent Claim
13 words
The method of claim 1 wherein the defect is a clotting factor inhibitor.
Claim 19
Independent Claim
51 words
A method for treating a patient having a clotting factor deficiency or inhibitor, comprising administering to the patient an effective hemostatic amount of a composition consisting essentially of factor VIIa, and wherein the factor VIIa is uncontaminated by other activated blood clotting factors having sufficient activity to produce a hemostatic effect.
Claim 20
Independent Claim
51 words
A method for treating a patient having a clotting factor deficiency or inhibitor, comprising administering to the patient an effective hemostatic amount of a composition consisting essentially of factor VIIa, and wherein the factor VIIa is uncontaminated by other activated blood clotting factors having sufficient activity to produce a hemostatic effect.
Claim 21
Dependent Claim
46 words
In a method for treating a patient having a clotting factor deficiency or inhibitor wherein an activated prothrombin complex containing factors VIIa, IXa and Xa is administered to the patient, the improvement comprising administering factor VIIa to the patient substantially free of factors IXa and Xa.
Claim 22
Dependent Claim
46 words
In a method for treating a patient having a clotting factor deficiency or inhibitor wherein an activated prothrombin complex containing factors VIIa, IXa and Xa is administered to the patient, the improvement comprising administering factor VIIa to the patient substantially free of factors IXa and Xa.
References Cited (Backward Citations)
US3560475A
Cited
US4160025A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-05-02 | 1986-11-01 | 1987-05-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-05-02 | 1990-11-01 | 1991-05-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-05-02 | 1994-11-01 | 1995-05-03 | $7700.00 | Window Closed / Lapsed |